Clinical Impact of Change of FLT3 Mutation Status in Acute Myeloid Leukemia (AML) Patients

被引：0
|
作者：
Warren, M.
Luthra, R.
Yin, C. C.
Ravandi, F.
Medeiros, L. J.
Zuo, Z.
机构：
[1] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LABORATORY INVESTIGATION | 2012年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1588
引用
收藏
页码：379A / 379A
页数：1
相关论文
共 50 条
  • [41] FLT3 inhibitors in acute myeloid leukemia
    Pastore, Domenico
    DRUGS AND CELL THERAPIES IN HEMATOLOGY, 2016, 4 (01): : 14 - 21
  • [42] FLT3 inhibitors in acute myeloid leukemia
    不详
    ANNALS OF HEMATOLOGY, 2008, 87 : S87 - S89
  • [43] FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia
    Ferrara, F.
    Leoni, F.
    Pollio, F.
    Viola, A.
    Pane, F.
    Ciolli, S.
    Palmieri, S.
    D'Amico, M. R.
    Vannucchi, A.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 51 - 51
  • [44] FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)
    Adamia, Sophia
    Nemeth, Jeffrey
    Bhatt, Shruti
    Walker, Sarah R.
    Voeks, Natalie I.
    Lento, William
    Attar, Ricardo M.
    Galinsky, Ilene
    Frank, David A.
    Wadleigh, Martha
    Letai, Anthony
    Steensma, David P.
    Weinstock, David M.
    DeAngelo, Daniel J.
    Dorfman, David M.
    Stone, Richard M.
    Griffin, James D.
    BLOOD, 2016, 128 (22)
  • [45] Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)
    Haddad, Fadi
    Medawar, Georgio
    Kanagal-Shamanna, Rashmi
    Alvarez, Hector
    Loghavi, Sanam
    Daver, Naval
    Pierce, Sherry A.
    Jabbour, Elias
    Kadia, Tapan M.
    Short, Nicholas
    DiNardo, Courtney D.
    Borthakur, Gautam
    Abbas, Hussein A.
    Pemmaraju, Naveen
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop
    Yilmaz, Musa
    BLOOD, 2022, 140 : 3196 - 3198
  • [46] Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
    Li, Chenglong
    Zhu, Biao
    Chen, Jiao
    Huang, Xiaobing
    MOLECULAR MEDICINE REPORTS, 2016, 14 (01) : 89 - 94
  • [47] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [48] More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML)
    Kusec, Rajko
    Jaksic, Ozren
    Ostojic, Slobodanka
    Kardum-Skelin, Ika
    Vrhovac, Radovan
    Jaksic, Branimir
    BLOOD, 2006, 108 (01) : 405 - 406
  • [49] FLT3 Gene Mutation Profile and Prognosis in Adult Acute Myeloid Leukemia
    Azari-Yam, Aileen
    Tavakkoly-Bazzaz, Javad
    Semnani, Yousef
    Davoudi-Dehaghani, Elham
    Ghodssi-Ghassemabadi, Robabeh
    Kianfar, Soodeh
    Saadat, Ameneh
    Masoudifard, Mahboobeh
    Yaghmaie, Marjan
    Alimoghaddam, Kamran
    Ghavamzadeh, Ardeshir
    Zeinali, Sirous
    CLINICAL LABORATORY, 2016, 62 (10) : 2011 - 2017
  • [50] Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia
    Weis, Taylor M.
    Marini, Bernard L.
    Bixby, Dale L.
    Perissinotti, Anthony J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 141 : 125 - 138
12345